Clinical Trial

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) non-small cell lung cancer after surgical resection.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-12.
Trial Details
NCT Number NCT06041776
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Enrollment 570 participants
Start Date 2023-03-28
Primary Completion 2028-04-30 (estimated)
Study Completion 2029-11-30 (estimated)
Updated on ClinicalTrials.gov 2023-09-22